Trial Profile
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jul 2023 Planned End Date changed from 1 May 2023 to 28 Feb 2025.
- 10 Jul 2023 Planned primary completion date changed from 1 May 2023 to 28 Feb 2025.
- 14 Jul 2021 Planned End Date changed from 2 Nov 2021 to 1 May 2023.